Intensive atorvastatin treatment on primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Objective:To investigate the clinical effects of single high dose atorvastatin before primary percutaneous coronary intervention(PCI) and intensive atorvastatin treatment after PCI in patients with ST-segment elevation myocardial infarction(STEMI). Method:A total of 118 cases were randomly divided into 2 groups: intensive atorvastatin group(61 cases) and conventional dose group(57 cases).In the intensive atorvastatin group,80 mg atorvastatin was applied before PCI and 40 mg/d after PCI,while conventional dose group was given atorvastatin 20 mg/d after PCI.Both groups were given conventional secondary prevention treatment.The primary end point was 30-day incidence of MACE.Secondary end points included myocardial perfusion TMPG grading,the rate of ST-segment resolution(STR) ≥50% immediately and 6 h after PCI and biochemical indicators at 30 d after PCI. Result:After 6 h of PCI,STR≥50% of the intensive atorvastatin group was significantly higher than that of the conventional dose group(86.9% vs 71.9%,P0.05).The level of CK-MB peak in intensive atorvastatin group was significantly lower than that of conventional dose group [(230.20±128.84)U/L∶(285.28±149.55)U/L,P0.05].Compared with the conventional dose group after treatment,LDL-C,hs-CRP of intensive atorvastatin group decreased significantly 30 d after PCI(P0.05). Conclusion:High-dose atorvastatin before PCI(80 mg) and 40 mg/d after PCI in patients with STEMI is effective and safe.STR of 6 h after PCI is improved significantly,and CK-MB peak,LDL-C and hs-CRP are decreased at 30 d after PCI.